Gracell Biotechnologies Inc. to Post Q1 2023 Earnings of Per Share, HC Wainwright Forecasts

GRCLDelisted Stock  USD 4.02  0.26  6.07%   
About 62% of Gracell Biotechnologies' investor base is looking to short. The analysis of current outlook of investing in Gracell Biotechnologies suggests that many traders are alarmed regarding Gracell Biotechnologies' prospects. Gracell Biotechnologies' investing sentiment shows overall attitude of investors towards Gracell Biotechnologies.
  
Gracell Biotechnologies Inc. Investment analysts at HC Wainwright issued their Q1 2023 EPS estimates for Gracell Biotechnologies in a research report issued to clients and investors on Monday, March 13th. HC Wainwright analyst E. Bodnar anticipates that the company will earn per share for the quarter. HC Wainwright has

Read at thelincolnianonline.com
news
  

Gracell Biotechnologies Fundamental Analysis

We analyze Gracell Biotechnologies' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gracell Biotechnologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gracell Biotechnologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Return On Equity

Return On Equity Comparative Analysis

Gracell Biotechnologies is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Gracell Biotechnologies Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Gracell Biotechnologies stock to make a market-neutral strategy. Peer analysis of Gracell Biotechnologies could also be used in its relative valuation, which is a method of valuing Gracell Biotechnologies by comparing valuation metrics with similar companies.

Peers

Gracell Biotechnologies Related Equities

GLUEMonte Rosa   13.72   
0%
100.0%
XFORX4 Pharmaceuticals   11.43   
0%
83.0%
CTMXCytomX Therapeutics   3.92   
0%
28.0%
BOLTBolt Biotherapeutics   1.59   
0%
11.0%
DAWNDay One   1.53   
0%
11.0%
BPMCBlueprint Medicines   1.35   
0%
9.0%
ASMBAssembly Biosciences   1.25   
0%
9.0%
SPROSpero Therapeutics   0.88   
0%
6.0%
DSGNDesign Therapeutics   0.50   
0%
3.0%
ABOSAcumen Pharmaceuticals   0.44   
0%
3.0%
INZYInozyme Pharma   0.37   
2.0%
0%
TERNTerns Pharmaceuticals   1.58   
11.0%
0%
ERASErasca   2.05   
14.0%
0%
NXTCNextCure   2.50   
18.0%
0%
CHRSCoherus BioSciences   3.17   
23.0%
0%
AMLXAmylyx Pharmaceuticals   3.48   
25.0%
0%
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Other Consideration for investing in Gracell Stock

If you are still planning to invest in Gracell Biotechnologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Gracell Biotechnologies' history and understand the potential risks before investing.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Fundamental Analysis
View fundamental data based on most recent published financial statements
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
CEOs Directory
Screen CEOs from public companies around the world
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets